

CURRICULUM VITAE

NAME: MAUREEN D. MAYES, M.D., M.P.H.

PRESENT TITLE: Professor of Internal Medicine
Division of Rheumatology and Clinical Immunogenetics

ADDRESS: University of Texas – Houston Health Science Center
6431 Fannin, MSB 5.270
Houston, Texas 77030
Phone: (713) 500-6905
Fax: 713-500-0580
E-mail: Maureen.D.Mayes@uth.tmc.edu

CITIZENSHIP: U.S. Citizen

UNDERGRADUATE EDUCATION:

1967 BA Degree (Chemistry), College of Notre Dame of Maryland,
Baltimore, MD

GRADUATE EDUCATION:

1970-1973 Graduate Student, Department of Biochemistry, University of
Virginia, Charlottesville, VA

1976 MD Degree, Eastern Virginia Medical School, Norfolk, VA

1994 MPH Epidemiology, University of Michigan School of Public Health,
Ann Arbor, MI

OTHER TRAINING AND EXPERIENCE:

1967-1968 Research Assistant, Biological Laboratories, Harvard University,
Cambridge, MA

1968-1969 Research Assistant, Virginia Associated Research Center of Virginia
Commonwealth University, Newport News, VA

POSTGRADUATE TRAINING:

- 1977-1979 Internal Medicine Intern and Resident, Cleveland Clinic Foundation, Cleveland, OH
- 1979-1981 Rheumatology Fellow, Cleveland Clinic Foundation, Cleveland, OH

MILITARY SERVICE: Not Applicable

ACADEMIC APPOINTMENTS:

- 1981-1985 Assistant Professor of Medicine, Division of Rheumatology, West Virginia University School of Medicine, Morgantown, WV
- 1985-1990 Assistant Professor of Medicine, Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
- 1990-1997 Associate Professor of Medicine (Clinician - Educator), Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
- 1997-2002 Adjunct Associate Professor of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
- 1997-2002 Professor of Medicine (Clinician - Educator), Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
- 2002-present Professor of Medicine, Division of Rheumatology and Clinical Immunogenetics, University of Texas-Houston Health Science Center

HOSPITAL APPOINTMENTS:

- 2002 Memorial Hermann Hospital
 LBJ Hospital
- 2004 MD Anderson Cancer Center
- 2004 St. Luke's Episcopal Hospital

LICENSURE:

- 1977 Licensure – State of Virginia, No. 0101-027979 (Inactive)
- 1985 Licensure - State of Michigan, No. 4301-048422 (Inactive)
- 2002 Licensure – State of Texas, No. L 4562 (Active)

CERTIFICATION:

- 1978 National Board of Medical Examiners
- 1980 American Board of Internal Medicine, No. 71012
- 1982 American Board of Internal Medicine, Subspecialty Board in Rheumatology, No. 71012

**PROFESSIONAL ORGANIZATIONS (AND COMMITTEES OF THESE):
LOCAL AND REGIONAL (Michigan):**

- 1995-2001 Member, Board of Trustees, Michigan Chapter, Arthritis Foundation
- 1997-2001 Member, Community Advisory Committee, University of Michigan, Multipurpose Arthritis & Musculoskeletal Diseases Center
- 1992-1995 Member, Arthritis Subcommittee, Chronic Disease Advisory Committee, Michigan Department of Public Health
- 1988-1990, 1991-1996; 1998-2000, 2001-2002 Member, Michigan Chapter, Arthritis Foundation Medical and Scientific Committee
- 1986-2001 Member, Michigan Chapter, Scleroderma Foundation Medical Advisory Board
- 2000-2001 Member, Arthritis 2000 Plan Steering Committee of the Michigan Department of Community Health

**PROFESSIONAL ORGANIZATIONS (AND COMMITTEES OF THESE):
NATIONAL:**

- American College of Physicians, Fellow
American College of Rheumatology, Fellow
Scleroderma Clinical Trials Consortium (SCTC), Executive Committee Member
- 1999 Member, American College of Rheumatology Abstract Review Committee for Scleroderma and Myopathies, 1999
- 1995-1997 Member, Central Region Council of the American College of Rheumatology

National Advisory Committees

- 2002 - 2004 Chair, Scientific Advisory Committee for the Childhood Onset

- Scleroderma Registry, funded by the Scleroderma Foundation, 2002 – 2004. Principal Investigator: Dr. Thomas Medsger, Jr., Professor of Internal Medicine, Division of Rheumatology, University of Pittsburgh
- 2002 - present Member, Medical Advisory Board, Scleroderma Foundation
(previously Chair 1996 – 2002)
- 2002 – 2005 Member, Advisory Committee for the ‘Michigan Study and Surveillance of Lupus,’ Michigan Dept of Community Health, funded by Centers for Disease Control, 2002
- 2001- present Co-Chair, Protocol Development Group for HDIT (High Dose Immunosuppressive Therapy) vs CTX (Cyclophosphamide) for severe Systemic Sclerosis, NIH/NIAID
- 2002 – 2005 Chair, Task Force for MicroArray Consortium, Scleroderma Foundation
- 2000 - 2005 Member, Executive Committee, Scleroderma Clinical Trials Consortium (past president)
- 2005 – present Member, Data Safety Monitoring Board, “Study of Alefacept in Scleroderma Lung Disease: Role of T Cells” funded by Biogen-Idec.
- 2005-present Member, Data Safety Monitoring Board, Novartis Study CAAE581C2201
- 2007 – present Member, External Advisory Panel of the SCCOR in Pulmonary Arterial Hypertension, Johns Hopkins University School of Medicine

HONORS & AWARDS:

Spirit of Hope Award, national Scleroderma Foundation, October, 2006.

Award for Best Poster (2 awards given from approximately 800 abstracts), Society of Behavioral Medicine Annual Meeting, San Diego, CA, March 6-9, 1999

Wayne State University School of Medicine, College Teaching Award, September 1998

Citation Paper Award, Biofeedback Society of America, March 1996

NIAMS Senior Research Fellowship, January 1994

Maureen D. Mayes, M.D., Award of Excellence, presented by the Southeast Michigan United Scleroderma Foundation, 1992

Women of Wayne Staff/Faculty Recognition Award-Honorable
Mention, May 1990

Citation Paper Award, Biofeedback Society of America, March
1987

Lower Award (Rheumatology Research), Cleveland Clinic
Foundation, 1981

J.J. Quarles, Sr., Memorial Scholarship, Eastern Virginia
Medical School 1974

Health Professions Scholarship, Eastern Virginia Medical School,
1973

NIH Fellow, Biochemistry Department, University of Virginia,
1971-1972

Listed in Castle Connolly Medical Ltd., America's Top Doctors, 2001,
2002, 2003, 2004.

Listed in Woodward/White, Inc., The Best Doctors in America.
Second, Third, and Fourth editions, 1994, 1996, 1998

Listed in Best Doctors, Inc. 2003, 2004, 2005, 2006

Listed in Texas Super Doctors (Texas Monthly magazine) 2006

EDITORIAL POSITIONS and Ad Hoc Reviewer Activities:

Editorial Board, Scleroderma Care and Research, 2003, 2004, 2005

Annals of Internal Medicine, 1999, 2001, 2004

Arthritis and Rheumatism, 1995, 1997, 1998, 1999, 2000, 2001, 2002,
2003, 2004, 2005, 2006

Arthritis Care and Research, 2005, 2006

Archives of Internal Medicine, 2004
Journal of Rheumatology, 2001, 2004, 2005, 2006

Journal of Clinical Investigation, 1998, 2000

Annals of the Rheumatic Diseases, 1998

Consultant: Consultations in Primary Care, 1998

Environmental Health Perspectives, 1999

American Journal of Medicine, 1989, 1990, 1994, 2003, 2004, 2005

Seminars in Arthritis & Rheumatism 2004

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS,
COMMITTEES:**

Ad hoc Reviewer, V.A. Grants Review Process, 1989, 1990, 1995

Ad hoc Grant Reviewer, NIH/National Institute of Environmental
Health Sciences (NIEHS), 1996, 2000.

Ad hoc Grant Reviewer, NIH/National Institute of Arthritis, Muscular-
Skeletal and Skin Diseases (NIAMS), 1998, 1999, 2000, 2003, 2004,
2005, 2006

Member, Study Section, Scleroderma Foundation National Grant
Review Committee, 1999, 2000, 2005, 2006

Ad hoc Grant Reviewer, NIH, National Institute of Dental and
Craniofacial Diseases Special Emphasis Panel, 2005-2007

Member, NIH/NIAMS P30 RDCC Review Panel, 2005 and 2007

Chair, Special Emphasis Panel, NIH/NIAMS, 2006

**SERVICE ON THE UNIVERSITY OF TEXAS-HOUSTON HEALTH SCIENCE CENTER
COMMITTEES: None**

**SERVICE ON THE UNIVERSITY OF TEXAS-HOUSTON MEDICAL SCHOOL
COMMITTEES:**

2002 Chair, Evidence-Based Medicine Task Force for the Internal Medicine
Residency Program

2002- Member, Scientific Advisory Committee for the UCRC

2004- Interviewer, Medical School Admissions Committee

2006 Member, Ad hoc Committee for Proposed Promotion of faculty member;
of the Faculty Appointments, Promotions and Tenure Committee.

SERVICE ON GRADUATE SCHOOL COMMITTEES: None

SERVICE ON UT-H MS AFFILIATED HOSPITAL COMMITTEES: None

SERVICE TO THE COMMUNITY:

- | | |
|-----------|---|
| 1986-1996 | Director, United Scleroderma Foundation National Board of Directors |
| 1988-1989 | President, National Board of Directors, United Scleroderma Foundation |
| 1994-2001 | Chair, National Medical Advisory Board, United Scleroderma Foundation |
| 2002- | Member, National Medical Advisory Board, Scleroderma Foundation, |

CURRENT TEACHING RESPONSIBILITIES:

Lecturer in 2nd year medical student Rheumatology small group case sessions
 Participant weekly Rheumatology Journal Club, Case Conference and monthly Rheumatology Grand Rounds for the TMC
 Rheumatology Consult and Teaching Rounds
 Attending on Medicine Teaching Service
 Faculty, Center for Clinical Research and Evidence Based Medicine and course instructor for 4th year medical student clinical epidemiology course 2002-2003, and Fall 2003.

SPONSORSHIP OF POSTDOCTORAL FELLOWS:

- a. Patricia Dhar, M.D., WSU postgraduate rheumatology fellow.
 Project: The development of auto-immune disease in a large population of bone marrow transplant patients. Presented at American Rheumatism Association Meeting, Washington, DC, June 1987. Arthritis Rheum 30 (Suppl): S36, 1987.
- b. A.D. Mosley, M.D., WSU postgraduate rheumatology fellow.
 Project: Long-standing alcohol abuse and chronic inflammatory polyarthritis. Presented at the MI. Chapter ACP Meeting, Grand Traverse Village, MI, September 1987.
- c. M.C. Haller, M.D., WSU postgraduate rheumatology fellow.
 Winner of Central Region American Rheumatism Association Fellows Award, November 1988. Project: Effects of Interleukin-I on collagenase activity of scleroderma cells in a collagen matrix. Clin Res 36:842a, 1988. Presented at Midwest AFCR Meeting, Chicago, IL, November 1988.

- Clinical Project: Hemophilus influenza arthritis mimicking acute gonococcal arthritis. Case report and review of the literature. Presented at Michigan ACP Meeting, Traverse City, MI, 1988
- d. C.J. Huebner, M.D., WSU postgraduate rheumatology fellow. Project: Polyarticular septic arthritis. Presented at Michigan ACP Meeting, Traverse City, MI, September 22, 1989; Project: Autoantibodies to collagen in scleroderma. Presented at Michigan ACP Meeting, Traverse City, MI, September 1990.
 - e. Kathy Hajj, M.D., WSU postgraduate medicine resident. Project: "Family studies in scleroderma," 1991.
 - f. Christine Adamick, WSU first year medical student. Summer research laboratory project: I1-6 as a mediator of elevated TIMP and collagen synthesis in scleroderma fibroblasts, 1991.
 - g. Mina Mark, M.D., WSU postgraduate rheumatology fellow. Project: The role of I1-6 in Scleroderma, 1992-1993.
 - h. Bassel Darwish, M.D., WSU postgraduate medical resident. Clinical research project: Hyperlipidemia and increased risk of cardiovascular complications in scleroderma, 1995.
 - i. Paul Gryzenia, WSU MS1. Clinical research project: Prevalence and incidence of scleroderma in Southeast Michigan, 1995.
 - j. Farrukh Anwar, M.D., WSU Rheumatology fellow. Clinical research project: The natural history of systemic sclerosis with diffuse skin involvement. July 1, 1999, to December 15, 1999.
 - k. Soumya Chatterjee, M.D., WSU Rheumatology fellow. Clinical research project: Epidemiological Features in Scleroderma. July 1, 2000, to June 30, 2001.
 - l. Daniel P. O'Donnell, WSU MS I. Summer clinical preceptorship funded by the American College of Rheumatology, Summer, 2001. Project: Minocycline in Scleroderma.
 - m. Carina Eastman, UT-H Summer Undergraduate Research Program. Clinical research project: Autoantibodies in Scleroderma Patients and their Family Members, Summer, 2002
 - n. Josh Barron, UT-H Summer Undergraduate Research Program. Pedigrees of Multicase Autoimmune Disease Families, Summer, 2003.
 - o. Shervin Assassi, MD, UT-H Rheumatology Fellow. Clinical research project: Characteristics of Scleroderma Multicase Families, 2003-2004.
 - p. Jo Elle Peterson, UT-H medical student summer research project: Prevalence of positive autoantibodies in first degree relatives of SSc patients, 2004.
 - q. Rachel Cohen, UT-H medical student summer research project: RNA-Polymerase III autoantibodies in Scleroderma Patients in the Scleroderma Registry, 2005.
 - r. Megan MacNeil, MD, UT-H Rheumatology Fellow. Clinical research project: Damage Index in the GENISOS Cohort, 2006.

- s. Rajpreet Arora, MD, UT-H Medicine Resident. Laboratory research project: Association of PDGF gene polymorphisms in scleroderma, 2006.
- t. Firas Alkassab, MD, UT-H Rheumatology Fellow. Clinical research project: Pulmonary function test abnormalities in the GENISOS cohort, 2006.

CURRENT GRANT SUPPORT:

- 2005 NIH/NIAID Subcontract from Duke University Medical Center. "A randomized, open-label, phase II/III Multicenter study of High-dose immunosuppressive therapy using total body irradiation, cyclophosphamide, ATGAM, and autologous transplantation with auto-CD34+HPC versus intravenous pulse cyclophosphamide for the treatment of severe systemic sclerosis. PI at UTH site. Total award \$828,158. Period of award: April 1,2005 to Sept. 21, 2012.
- 2005 NIH/NIAID R34 Planning Grant for one year
Title: Allogeneic Transplantation for Severe Systemic Scleroderma
Proposed Period of Award: January 2006 through December 2006.
Principal Investigator: Richard Nash, Fred Hutchinson Cancer Center, Seattle. Co-Investigator: MD Mayes (Principal Investigator at UT-Houston site). Total Award for Project at UT-Houston: \$25,825. Period of award: July 2006 to June, 2007.
- 2005 Actelion Pharmaceuticals, Inc., RAPIDS-2 Open Label Extension Study: A multi-center open label study to assess long term safety and the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis. PI at UTH site. Total award \$60,000. Period of award: October, 2005 to October, 2008
- 2006 NIH/NIAMS P50 CORT (Center of Research Translation) Grant
PI of Project 2: Gene Expression as Predictors of Outcome in the GENISOS (Genes versus Environment in Scleroderma Outcome Study) Cohort
Program Project Director: FC Arnett
Proposed Period of Award: September 2006 through August 2010
Total Award for Project: \$9.8 million
- 2006 Department of Defense: Candidate Gene Polymorphisms in Scleroderma: Defining Susceptibility Factors
Principal Investigator: MD Mayes
Proposed Period of Award: July, 2007 through June 2012
Total Award for Project: \$625,000

GRANTS SUBMITTED:

- 2006 NIH/NHLBI Scleroderma Lung Study II: Multicenter study of Cyclophosphamide versus Mycophenylate Mofetil for the treatment of scleroderma lung disease
Principal Investigator: D. Tashkin, UCLA
Co-Investigator: MD Mayes (Principal Investigator at UT-Houston site)
Proposed Period of Award: July, 2007 through June 2012
- 2006 NIH/NIAMS Genome-Wide Association Study in Systemic Sclerosis
Principal Investigator: MD Mayes
Proposed Period of Award: July, 2007 through June 2012

PAST GRANT SUPPORT:

- 1982 West Virginia University Biomedical Grant, "Lymphocyte Macrophage Interaction in Scleroderma," P.I. MD Mayes, \$4,900, 1982-1983
- 1983 United Scleroderma Foundation, "Immunocytochemical study of the Connective Tissue Matrix in PSS (Progressive Systemic Sclerosis)," P.I. MD Mayes, \$10,000, 1983-1984
- 1988 Michigan Chapter, Arthritis Foundation, "Regulation of Collagen Metabolism by Scleroderma Fibroblasts," \$9,231, P.I. MD Mayes, Period of award: January 1988-December 1989.
- 1989 Harper Hospital Medical Staff Trust Fund, "Study of Collagen Metabolism in a Collagen Matrix," \$30,484. P.I. MD Mayes. Period of award: January 1989-December 1989.
- 1989 Michigan Chapter Arthritis Foundation, continuation of "Regulation of Collagen Metabolism by Scleroderma Fibroblasts," \$10,000. P.I. MD Mayes. Period of award: January 1989-December 1989.
- 1989 Berlex Laboratories, "Study of Intravenous Iloprost in patients with Raynaud's Phenomenon Secondary to Scleroderma," \$67,959. Period of award: January 1989-December 1989. P.I. MD Mayes.
- 1989 Glenwood Laboratories, University of Utah subcontract, participating clinic, "Comparison of Potaba and Placebo in the treatment of Scleroderma," \$51,800. Period of award: June 1989-February 1990. P.I. MD Mayes.
- 1990 Glenwood Laboratories, extension of subcontract: March 1, 1990-February 28, 1991.
- 1991 Upjohn Company, "A Twelve Week Comparison of Ansaïd Tablets with Naprosyn Using Flexible Dosing Schedules for the Disease

- Management of Patients with Rheumatoid Arthritis,” \$48,200. Period of award: January 1, 1991-December 31, 1991. P.I. MD Mayes.
- 1991 Dow-Corning Corp., “The Epidemiology of Scleroderma: A population-based case-control study.” Co-Investigator, 5% salary. Period of award: July 1, 1991-June 30, 1996.
- 1992 Centocor, “Phase II Study of Chimeric Anti-CD4 in patients with Rheumatoid Arthritis on a Stable Regimen of Low Dose Methotrexate,” \$94,891. Period of award: November 1, 1992-October 1, 1997.P.I. MD Mayes.
- 1993 Michigan Chapter Arthritis Foundation, “Interleukin 6 and Tissue Inhibitors of Metalloproteinases (TIMP-1 and TIMP-2) in Systemic Sclerosis,” \$10,000. Principal Investigator. Period of award: January 1, 1993- December 31, 1993. P.I. MD Mayes.
- 1994 Michigan Chapter Arthritis Foundation, “Myofibroblasts in Scleroderma,” \$10,000. Period of award: January 1994-December 1994. P.I. MD Mayes.
- 1994 NIH, National Research Service Award, Senior Fellowship Application (F-33), salary support of \$32,500, “Prevalence, Incidence and Mortality of Scleroderma in the Detroit Metropolitan Area.” Period of award: January 1994-August 1994, to include course work for the M.P.H. degree at the School of Public Health, University of Michigan Department of Epidemiology.
- 1994 Connective Therapeutics, “Clinical Trial of Relaxin in Scleroderma,” Principal Investigator at W.S.U. site, \$16,685. Period of award: December 1, 1994-November 30, 1995.
- 1994 NIAMS Contract “Scleroderma Research Registry,” Principal Investigator, \$832,085.Period of award: October 5, 1994-October 4, 1999.
- 1995 Therakos, a division of Johnson & Johnson, “Photopheresis in Scleroderma,” Principal Investigator at W.S.U. site, \$573,576. Period of award: January 15, 1995-January 14, 1998.
- 1995 Berlex Laboratories, “Oral Iloprost for the Treatment of Raynaud’s Phenomenon Secondary to Systemic Sclerosis,” Principal Investigator at W.S.U. site, \$69,150. Period of award: December 1995-November 1996.
- 1996 Connective Therapeutics, “A Phase I Study of Subcutaneous Continuous Infusion of Recombinant Human Relaxin Manufactured by a Single Chain Process in Patients with Systemic Sclerosis with Diffuse

- Scleroderma,” Principal Investigator at W.S.U. site, \$31,256. Period of Award: February 1996-January 1997.
- 1996 NIH, “Behavioral Treatment of Raynaud’s Phenomenon,” Co-Investigator (20% time for first 2 years, then 10% time), \$257,054 (total costs for entire period). Period of award: January 1, 1997-June 30, 2000.
- 1997 Glaxo Wellcome, “A Multicenter, Open-label, Randomized, Parallel Comparison of the Safety and Efficacy of Chronic FLOLAN Infusions to Conventional Therapy Alone in Patients with Isolated Pulmonary Hypertension Secondary to the Scleroderma Spectrum of Diseases: A Twelve-Week Study,” Co-Investigator at W.S.U. site, \$200,011. Period of Award: January 1, 1997-December 1998.
- 1998 Connetics Corporation, “A Phase II/III Placebo-Controlled Safety and Efficacy Study of Recombinant Human Relaxin Therapy in Subjects with Systemic Sclerosis with Diffuse Scleroderma,” Principal Investigator at W.S.U. site. Period of Award: February 1999-January 2002.
- 1999 NIH/NIAMS, one-year funded extension of Scleroderma Research Registry, Principal Investigator (30% time), \$170,578 (total costs for one-year extension). Period of award: 10/1/1999-9/30/2000.
- 1999 NIH/NHLBI, "Scleroderma Lung Study: Oral Cyclophosphamide vs. Oral Placebo in SSc Pulmonary Alveolitis," Co-Investigator 1999-2000, now Principal Investigator at UTH site (5% time), \$255,788. Period of Award: October 1, 1999-September 30, 2004, no cost extension to 9/05.
- 1999 NIH/NIAMS, “Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma,” Principal Investigator at UTH site (5% for first year, then 15%), \$201,282 (total costs at WSU then UTH site for entire period). Period of Award: October 1, 1999-September 30, 2004, no cost extension to 9/05.
- 2000 NIH/NIAMS, “Scleroderma Family Registry and DNA Repository,” P.I. (20% time), \$4,400,234 total award. Period of Award: September 30, 2000 – September 29, 2005, no cost extension to September 29, 2006.
- 2001 Research and Education Foundation of the American College of Rheumatology Summer Medical Student Summer Clinical Fellowship Award, \$3,000 (Dr. Mayes as preceptor with Dr. Mosley-Williams).
- 2001 NIH/NIAMS, R21 “Study of Persistent Infections in SSc Skin and Vessels,” P.I., (5% time) \$335,250. Period of award: September 30, 2001 – September 29, 2004, no cost extension to 9/06.

- 2003 Genzyme Corporation “A Phase I/Phase II Double-blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of CAT-192 Human Anti-TGF β 1 Monoclonal Antibody in Patients with Diffuse Systemic Sclerosis. Principal Investigator at UTH site. Total award \$47,620. Period of award: September 15, 2002 to September 15, 2003.
- 2003 NIH/NIAMS, Project 3 of Scleroderma SCOR “Genes versus Environment in Scleroderma Outcomes Study (GENISOS),” P.I. as of November 2003 (replacing Dr. John Reveille), 20% time and effort. Period of award: Sept. 1, 2001 to Aug. 31, 2006.
- 2003 Actelion Pharmaceuticals, Inc., BUILD 2 Study: Double-blind, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of Bosentan in patients with interstitial lung disease associated with systemic sclerosis. PI at UTH site. Total award \$170,000. Period of award: Aug. 1, 2003 to Jan. 1, 2006
- 2003 Minority Supplement award to the GENISOS project (noted above). Mentor for Dr. A. Robles, Pulmonary Medicine. Total award \$348,855. Period of award: September, 2003 to February, 2006 (truncated due to Dr. Robles leaving the institution).
- 2003 Actelion Pharmaceuticals, Inc., RAPIDS-2 Study: A Randomized, double blind, placebo-controlled, multi-center study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis. PI at UTH site. Total award \$60,000. Period of award: October, 2003 to October, 2005.
- 2004 Genzyme Corporation: Clinical Screening Protocol to Characterize the Clinical Status of Patients with Diffuse Systemic Sclerosis for Inclusion in a Clinical Trial. PI at UTH site. Total award \$5,200. Period of award: January 2004 to October 2004.

PUBLICATIONS:

A. PUBLISHED ABSTRACTS (since 1996):

1. Clements P, Furst D, Mayes M, McCloskey D, Moreland L, White B, Wigley F, Rocco S, Mangan C, Erickson M, Sanders M, and Amento E. Safety and Pharmacokinetics of Recombinant Human Relaxin in Scleroderma (SSc). *Arthritis Rheum* 39 (Suppl): S152, 1996.
2. Mayes M, Laing T, Gillespie B, Cooper B, Lacey Jr. J, Hirschenberger W, Atty S, and Schottenfeld D. Prevalence

- incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. *Arthritis Rheum* 39 (Suppl): S150, 1996.
3. Laing T, Gillespie B, Lacey Jr. J, Garabrant D, Cooper B, Heeringa S, Alcsér K, Sungwon C, Mayes M, and Schottenfeld D. The association between silicone exposure and undifferentiated connective tissue disease among women in Michigan and Ohio. *Arthritis Rheum* 39 (Suppl): S150, 1996.
 4. Seibold JR, McCloskey DA, Clements PJ, Mayes MD, Rocco SE, Harkonen WS, and Sanders ME. Six month pilot trial of recombinant human relaxin (rhRlx) in diffuse scleroderma. *Brit J of Rheumatol* 36 (Suppl 1): 29, 1997.
 5. Lacey Jr. JV, Garabrant DH, Gillespie BW, Cooper BC, Laing TJ, Mayes MD, and Schottenfeld D. Self-reported exposure to solvents in women with systemic sclerosis (SSc). *Arthritis Rheum* 40 (Suppl): S201, 1997.
 6. Beebe JL, Lacey Jr. JV, Mayes MD, Gillespie BW, Cooper BC, Laing TJ, and Schottenfeld D. Reproductive history, oral contraceptive use, estrogen replacement therapy and the risk of developing scleroderma. *Arthritis Rheum* 40 (Suppl): S100, 1997.
 7. Lacey Jr. JV, Garabrant DH, Gillespie BW, Cooper BC, Laing TJ, Mayes MD, and Schottenfeld D. Self-reported exposure to solvents in women with undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 40 (Suppl): S201, 1997.
 8. Lacey Jr. JV, Beebe JL, Mayes MD, Gillespie BW, Laing TJ, Cooper BC, and Schottenfeld D. Reproductive history, oral contraceptive use, and estrogen replacement therapy in women with undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 40 (Suppl): S119, 1997.
 9. Korn J, Simms R, Clements PJ, Moreland L, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, DeMarco P, Collier D, Wigley F, Merkel PA, Csuka ME, Rocco S, Erikson M, Hannigan J, Harkonen WS, and Sanders ME. Controlled trial of recombinant human relaxin (rhRlxn) in diffuse scleroderma (DS). *Arthritis Rheum* 40 (Suppl): S123, 1997.
 10. Clements PJ, Wong WK, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Weinstein A, Medsger Jr. T, Steen V, Martin R, Moreland L, Collier D, Lally E, Varga J, Andrews B, Weiner S, and Abeles M. High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of trial. *Arthritis Rheum* 40 (Suppl): S173, 1997.
 11. Kirk TZ, and Mayes MD. Abnormal apoptosis in scleroderma myofibroblasts. Abstract presented at the International Scleroderma Conference, Montecatini Terme, Italy, March, 1998. *Clin Exp Rheum* 16(3): 367, 1998.
 12. Doss B, Jacques SM, Atty S, Mayes MD, and Qureshi F. Maternal

- Scleroderma: placental findings and perinatal outcome. *Human Pathology* 28:1524-1530, 1998.
13. DeMarco PJ, Weisman M, Wong WK, Clements PJ, and the High Dose vs Low Dose Penicillamine in SSc Trial Investigators. Predictors and outcome of scleroderma renal crisis in an early disease (<18 months) cohort of patients followed for 4 years. *Arthritis Rheum* 41 (Supp): S239, 1998.
 14. Injic Z, and Mayes MD. The use of indwelling venous catheters in patients with systemic sclerosis (SSc). *Arthritis Rheum* 41 (Supp): S183, 1998.
 15. Lacey Jr. JV, Mayes MD, Laing TJ, Gillespie BW, Garabrant DH, and Schottenfeld D. Self-reported medical history and medication use among women with undifferentiated connective tissue disease. *Arthritis Rheum* 41 (Supp): S336, 1998.
 16. Lacey Jr. JV, Garabrant DH, Mayes MD, Laing TJ, Gillespie BW, and Schottenfeld D. Self-reported exposure to pesticides and herbicides as risk factors for undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 41 (Supp): S336, 1998.
 17. Herlyn K, Martin RW, Schoenfeld DA, Merkel PA, and Scleroderma Clinical Trials Consortium. Association between climatic factors and severity of Raynaud's Phenomenon in patients with systemic sclerosis. *Arthritis Rheum* 41 (Supp): S216, 1998.
 18. Aguilar MB, Cho M, Reveille JD, Mayes MD, and Arnett FC. Prevalence of familial systemic sclerosis and other autoimmune diseases in three U.S. cohorts. *Arthritis Rheum* (Supp): S186, 1999.
 19. Nash RA, Dansey R, Storek J, Sullivan KM, Pavletic S, McDonagh KT, Kraft GH, Mayes MD, Forman SJ, Holmberg LA, and McSweeney PA. Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases. *American Society of Hematology*, 2000.
 20. Chatterjee S, Severson RK, Weiss LK, Kau T-Y, and Mayes MD. Risk of Malignancy in Scleroderma. *Arthritis Rheum* 43 (Supp): S315, 2000.
 21. Furst DE, McSweeney P, Nash R, Holmberg I, Viganego F, Nelson L, Wener M, McDonagh K, Crofford L, Storek J, Agee G, Ryan K, Prather K, Mayes M, Dansey R, and Sullivan K. High-dose immunosuppressive therapy (HDIT) with autologous stem cell transplantation (SCT) for systemic sclerosis (SSc): results in the first 8 patients. *Arthritis Rheum* 43 (Supp): S392, 2000.
 22. Seibold JR, Clements PJ, Korn JH, Ellman M, Rothfield NF, Wigley FM, Moreland LW, Kim Y, Silver RM, Furst DE, Steen VD, Firestein GS, Kavanaugh AF, Mayes MD, Collier D, Csuka ME, Simms R, Merkel P, Medsger TA, Erikson M, Rocco S, Hannigan J, Sanders ME. US. Phase III Trial of Relaxin in Diffuse Scleroderma. Presented at the ILAR (International League against Rheumatism) meeting, Edmonton, Canada, August, 2001.

23. Furst DE, McSweeney P, Nash R, Storek J, Crofford LJ, McDonagh KT, Mayes M, Dansey RD, Colburn KK, Chen C-S, Sullivan KM. One year outcome of autologous stem cell transplantation (SCT) in 19 patients with severe SSc. *Arthritis Rheum* 46 (Supp): S267, 2001.
24. Mayes MD, O'Donnell D, Csuka ME, Rothfield NF. Multicenter, open-label trial of minocycline in early diffuse SSc. *Arthritis Rheum* 47 (Supp): S357, 2002.
25. Black C, Korn J, Mayes M, Rainisio M, Gaitonde M, Nguyen N, on behalf of the RAPIDS-1 Study Group. An exploratory, double-blind, randomized, placebo-controlled study on the prevention of ischemic digital ulcers secondary to systemic sclerosis. Late-breaking abstract, American College of Rheumatology annual meeting, New Orleans, LA, October, 2002.
26. Assassi S, Tercero GM, Reveille JD, Arnett FC, Mayes MD, McNearney T, Fischbach M, Tan, FK. Polymorphisms of the endothelial nitric oxide synthase and angiotensin conversion enzyme show no association with systemic sclerosis. *Arthritis Rheum* 48 (Supp): S159, 2003.
27. Mayes MD, Lee J, Luo J, Li J, Tan FD, Arnett FC, Tan FK. Candidate gene regions associated with systemic sclerosis (SSc): A family-based association study using TDT analysis. *Arthritis Rheum* 48 (Supp): S227, 2003.
28. Black CM, Korn JH, Mayes MD, Matucci-Cerinic M, for the RAPIDS-1 Study Group. Improvements in the net ulcer burden and hand functionality in patients with digital ulcers related to systemic sclerosis. *Arthritis Rheum* 48 (Supp): S454, 2003.
29. Furst DE, Nash RA, McSweeney P, Storek J, Georges E, Holmberg LA, Kraft GH, Mayes MD, McDonagh K, DiPersion J, LeMaistre F, Chen CS, Pavletic S, Sullivan K, Sunderhaus J, Dansey R. Intensive immunosuppression, particularly using higher dose rabbit ATG, may predispose to post transplantation lymphoproliferative disease (PTLD) in patients undergoing high dose immunosuppression with stem cell transplantation (SCT). *Arthritis Rheum* 48 (Supp): S626, 2003.
30. Clements PH, Khanna D, Furst DE, Sterz M, Chon Y, Lin R, Tashkin D, Elashoff R for the Scleroderma Lung Study Investigators. The degree of dyspnea correlates with health related quality of life (HRQOL), functional abilities, patient global assessment, forced vital capacity (%FVC) and diffusing capacity (%DLCO) in systemic sclerosis (SSc) patients with active alveolitis. *Arthritis Rheum* 48 (Supp): S558, 2003.
31. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Seibold JR, for the Relaxin Study Group. Responsiveness of the health related quality of life (HRQOL) instruments (SF 36 and HAQ-DI) in a systemic sclerosis (SSc) clinical trial. *Arthritis Rheum* 48 (Supp): S398, 2003.
32. Mayes MD, Zhang G, Luo J, Jin L, Tan FK, Arnett FC. Candidate genes associated with systemic sclerosis (SSc): A family-based genetic association study using 116 SNP's. *Arthritis Rheum* 50 (Supp): S622, 2004.

33. Tan FK, Hildebrand BA, Lester MS, Wallis D, Milewicz DM, Zhou X, Mayes MD, Arnett FC. Classification analysis of the transcriptome of dermal fibroblasts from systemic sclerosis (SSc) patients. *Arthritis Rheum* 50 (Supp): S621, 2004.
34. McSweeney PA, Furst DE, Crofford LJ, McDonagh KT, Sullivan KM, Mayes MD, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Lee J, Henstorff G, Abidi M, Nash RA. High-Dose Immunosuppressive Therapy for Severe Systemic Sclerosis: Long-term follow-up demonstrates continued improvement in function and skin with stability in the lungs. *Blood* 104:46a (abstract), 2004.
35. Suarez-Almazor M, Blanco A, Reveille JD, Mayes M. Disease and symptom burden in systemic sclerosis: the patients' perspective. *Arthritis Rheum* 50 (Supp): S423, 2004.
36. Wigley FM, Mayes MD, Lima JAC, McLain DA, Chapin L, Ward-Able C. The point prevalence of undiagnosed pulmonary hypertension (PAH) in patients with connective tissue disease (CTD) attending community based rheumatology clinics (UNCOVER Study). *Arthritis Rheum* 50 (Supp): S424, 2004.
37. Furst DE, McSweeney PA, Crofford LJ, McDonagh KT, Sullivan KM, Mayes MD, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Lee J, Henstorff G, Abidi M, Nash RA. High-Dose Immunosuppressive Therapy (HDIT) for SSc: Results of 3 year follow-up demonstrates continued improvement in function and skin with stability in the lungs. *Arthritis Rheum* 50 (Supp): S693, 2004.
38. Mayes MD, Zhang G, Luo L, Jin L, Tan FK, Arnett FC. Polymorphisms in the *ESRRG* (Estrogen Receptor Related Gamma) gene are associated with Systemic Sclerosis (SSc). *Arthritis Rheum* 52 (Supp) S365:2005.
39. Mayes MD, Ahn C, Arnett FC, Reveille JD. HLA Class II Associations in Systemic Sclerosis (SSc) from the Scleroderma Family Registry and DNA Repository. *Arthritis Rheum* 52 (Supp) S582:2005.
40. Peterson JEG, Perry MF, Arnett FCA, Mayes MD. Antinuclear Antibodies and non-SSc Autoimmune Diseases in First-degree Relatives of Scleroderma Patients: Data from the Scleroderma Family Registry and DNA Repository. *Arthritis Rheum* 52 (Supp) S583:2005.
41. Gardner HAR, Trojanowska M, Smith E, Pannu J, Shearstone J, Bandaru R, Tan FK, Mayes MD. Intact scleroderma biopsies have a strong transcript profile fingerprint which is incompletely reflected by explant fibroblast cultures. *Arthritis Rheum* 52 (Supp) S462:2005.
42. Gourh P, Assassi S, Watson K, Mayes MD, Tan F, Arnett FC. Association of Functional *PTPN22* 1858 C→T Polymorphism with Systemic Sclerosis. *Arthritis Rheum* 52 (Supp) S369:2005.
43. McNearney TA, Fischbach M, Reveille JDR, Goel N, Lisse JR, Ahn C, Arnett FC, Feghali C, Mayes MD. Early pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors in the GENISOS cohort. *Arthritis Rheum* 52 (Supp) S172:2005.

44. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR for the Scleroderma Clinical Trials Consortium (SCTC). Performance of the Modified Rodnan Skin Score in clinical trials of scleroderma. *Arthritis Rheum* 52 (Supp) S283:2005.
45. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR for the Scleroderma Clinical Trials Consortium (SCTC). Patterns and predictors of change in outcome measures in clinical trials in scleroderma. *Arthritis Rheum* 52 (Supp) S282:2005.
46. MacNeil MC, Ahn CW, McNearney T, Fischbach M, Feghali-Bostwick C, Fritzler M, Reveille JD, Arnett FC, Mayes MD. Application of the scleroderma disease severity scale to a multiethnic prospective early disease cohort: Data from the GENISOS (Genes versus Environment in Scleroderma Outcome Study) cohort. *Arthritis Rheum* 52 (Supp) S171: 2005.
47. Tan F, Zhou X, Mayes MD, Marcum C, Gio X, Gourh P, Jin L, Arnett Jr, FC. Gene expression signatures of vasculotropism in peripheral blood cells from patients with early systemic sclerosis. *Arthritis Rheum* 52 (Supp) S366: 2005.
48. Seibold JR, Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, Morganti A, Korn JH. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. *EULAR* 2006.
49. Gourh P, Tan FK, Mayes MD, Arnett FC. Association of functional *TYK2* V362F polymorphism with systemic sclerosis. *Arthritis Rheum* 54 (Supp) L17:2006.
50. Arora-Singh RK, Gourh P, Tan F, Perry M, Mayes MD. *PDGF* gene polymorphisms are associated with scleroderma in Caucasians for the scleroderma Registry. *Arthritis Rheum* 54 (Supp) L18:2006.
51. Alkassab F, Arnett FC, Reveille JD, Ahn C, McNearney TA, Fischbach M, Estrada-y-Martin R, Feghali-Bostwick C, Fritzler M, Williams L, Mayes MD. Persistence of pulmonary function tests (PFTs) abnormalities in African American systemic sclerosis (SSc) patients compared to Caucasian and Hispanic patients in the GENISOS cohort. *Arthritis Rheum* 54 (Supp) F60:2006.
52. Nash RA, McSweeney PA, Crofford JL, McDonagh KT, Sullivan KM, Mayes M, Nelson JL, Gooley T, Holmberg L, Shulman H, Wener M, McLaughlin B, Henstorf G, Molitor J, Seibold JR, Furst DE. 5-year follow-up of high-dose immunosuppressive therapy (HDIT) for systemic sclerosis (SSc). *Arthritis Rheum* 54 (Supp) S315:2006.
53. Suarez-Almazor ME, Kriseman JL, Kallen MA, Mayes MD. Impact of illness and symptom burden in patients with systemic sclerosis. *Arthritis Rheum* 54 (Supp) S484:2006.
54. Assassi S, Arnett FC, Reveille JD, Gourh P, Tan FK, Mayes MD. Disease features, disease type HLA types and autoantibody profile in 17 multicase SSc families. *Arthritis Rheum* 54 (Supp) S485:2006.

55. Alkassab F, Gourh P, Tan FK, McNearney TA, Fischbach M, Ahn C, Arnett FC, Mayes MD. An allograft inflammatory factor 1 (*AIFI*) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. *Arthritis Rheum* 54 (Supp) S732:2006.
56. Pope JE, Black C, Matucci-Cerinic M, Denton CP, Furst DE, Korn JH, Mayes MD, Morganti A, Seibold JR. Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc). *Arthritis Rheum* 54 (Supp) S740:2006.
57. Arora-Singh RK, Gourh P, Mayes MD, Arnett FC, Tan FK. Association of T-box transcription factor T-bet (*TBX21*) Polymorphism with Systemic Sclerosis, presented at the International Workshop on Systemic Sclerosis: Gene Polymorphisms, Clinical Variant and Response to Therapy, Milan Italy, 3/7 to 3/10/2007.
58. Arora-Singh RK, Gourh P, Divecha D, Arnett FC, Tan FK, Mayes MD. Association of *Topoisomerase 1* Gene Polymorphisms with Systemic Sclerosis from the Scleroderma Registry. (Fellow abstract) (657) F119 *Arthritis Rheum* 56;4302: 2007.
59. Sutter K, Gourh P, Mayes MD, Arnett FC, Tan FK. Association of IL2RA Polymorphisms with Limited Systemic Sclerosis. (Fellow abstract) (659) F121 *Arthritis Rheum* 56:4304:2007.
60. Sule SD, Hummers L, Shapiro L, Fiorentino D, Chung L, Baron M, Shanahan J, Hsu V, Rothfield N, Steen V, Martin R, Dugowson C, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Klaff L, Dechow FJ, Gregory J, Wigley FM. Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon. *Arthritis Rheum* 56 (Supp): S62, 2007.
61. Gourh P, Arnett FC, Shete S, Mayes MD, Tan FK. Gene-Gene Interactions Mediating Susceptibility to Scleroderma: Investigation of A 3 Gene Network. *Arthritis Rheum* 56 (Supp): S66, 2007.
62. Gourh P, Zhou X, Assassi S, Arnett FC, Tan FK. Comparative Analysis of Dermal Fibroblast Gene Expression Profiles from Patients with Systemic Sclerosis and Hypertrophic Burn Scars. *Arthritis Rheum* 56 (Supp): S66, 2007.
64. Assassi S, Mayes MD, Gourh P, Arnett FC, Reveille JD, Poage C, McNearney T, Fischbach M, Tan FK. Systemic Sclerosis and Systemic Lupus Erythematosus have Distinct Gene Expression Profiles in the Peripheral Blood Cells. *Arthritis Rheum* 56 (Supp): S67, 2007.
65. Alkassab F, Ruchdi KB, Verani RR, Mayes MD, Dosekun AK. Lupus Nephritis in Patients with Longstanding Limited Scleroderma: A Report of Two Patients. *Arthritis Rheum* 56 (Supp): S489, 2007.
66. Schioppa E, Hsu V, Hummers L, Shapiro LS, Mayes MD, Csuka ME, Derk CT, Chung LS, Varga J, Furst DE, Silver RM, Wigley FM, Seibold JR, Steen VD. Pulmonary Hypertension (PH)-Assessment and Recognition of

- Out-comes in Scleroderma (Systemic Sclerosis, SSc): PHAROS. *Arthritis Rheum* 56 (Supp): S489, 2007.
67. Khanna D, Lovell DE, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE. Development of a Provisional Core Set of Response Measures for Clinical Trials of Systemic Sclerosis. *Arthritis Rheum* 56 (Supp): S823, 2007.
 68. Chung L, Baron M, Collier D, Csuka ME, Fiorentino D, Gruber B, Hsu V, Kahaleh B, Martin R, Mayes MD, Pope J, Rothfield N, Shanahan J, Shapiro L, Simms R, Smith E, Steen V, Sule S, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Wigley FM. A Multi-Center Placebo-Controlled “In-Life” Study of MQX-503 in Patients with Raynaud Phenomenon. *Arthritis Rheum* 56 (Supp): S824, 2007.
 69. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Wigley FM. MQX-503, A Novel Topic Nitroglycerin Formulation, Improves Severity of Raynaud Phenomenon in a Heterogenous Patient Population. *Arthritis Rheum* 56 (Supp): S825, 2007.

B. Refereed Original Articles in Journals

1. Wysenbeek AJ, Mandel DR, **Mayes MD**, and Clough JD. Autoantibodies in systemic lupus erythematosus of late onset. *Cleve Clin Q* 52: 119-122, 1985.
2. Bathon J, Jens P, Graves J, Hamrick R, and **Mayes MD**. The erythrocyte sedimentation rate in end-stage renal failure. *Am J Kidney Dis* 10:34-40, 1987.
3. **Mayes MD**, Walker ER, Frederickson RG, Prince RK, and DiBartolomeo AG. The characterization of normal and scleroderma skin fibroblasts in a collagen gel matrix. *J Rheumatol* 15:268-275, 1988.
4. Freedman RR, Sabharwal SC, Ianni P, Desai N, Wenig P, and **Mayes MD**. Non-neural beta-adrenergic vasodilating mechanisms in temperature biofeedback. *Psychosom Med* 50: 394-401, 1988.
5. Freedman RR, Morris M, Norton DA, Masselink D, Sabharwal SC, and **Mayes MD**. Physiological mechanism of digital vasoconstriction training. *Biofeedback Self Regul.* 13:299-305, 1988.
6. Walker ER, Frederickson RG, and **Mayes MD**. The mineralization of elastic fibers and alterations of extracellular matrix in pseudoxanthoma elasticum. Ultrastructure, immunocytochemistry, and X-ray analysis. *Arch Dermatol* 125: 70-76, 1989.
7. Freedman RR, Sabharwal SC, Desai N, Wenig P, and **Mayes MD**. Increased alpha-adrenergic responsiveness in idiopathic Raynaud’s disease. *Arthritis Rheum* 32:61-65, 1989.
8. Freedman RR, **Mayes MD**, and Sabharwal SC. Induction of vasospastic

- attacks despite digital nerve block in Raynaud's disease and phenomenon. *Circulation* 80:859-862, 1989.
9. Freedman RR, **Mayes MD**, and Sabharwal SC. Digital nerve blockade in Raynaud's disease. *Circulation*. 80:123-124, 1989.
 10. Karvonen RL, Negendank WG, Fraser SM, **Mayes MD**, An T, and Fernandez-Madrid F. Articular cartilage defects of the knees: Correlation between magnetic resonance imaging and gross pathology. *Ann Rheum Dis* 49:672-675, 1990.
 11. Freedman RR, Keegan D, Migaly P, Galloway MP, and **Mayes MD**. Plasma catecholamines during behavioral treatments for Raynaud's Disease. *Psychosom Med* 53:433-439, 1991.
 12. Freedman RR, Moten M, Migaly P, and **Mayes MD**. Cold-induced potentiation of α_2 -adrenergic vasoconstriction in primary Raynaud's disease. *Arthritis Rheum* 36:685-690, 1993.
 13. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman A, Allegar N, Varga J, Massa M, Wigley FW, Ingenito F, Weisman M, Needleman B, Martin RW, McCloskey D, Moreland LW, **Mayes MD**, Lally EV, Unanue M, Collier DH, Weiner S, Weinstein A, Medsger TA Jr., Andrews B, Dixon M, White B and Furst DE. Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies. *J Rheum* 20:1892-1896, 1993.
 14. Seibold JR, Wigley FM, **Mayes MD**, Medsger T, Kujala G, Porter J, Jimenez S, Kaufman L, Wise C, Weiner S, Clements PJ, Wise RA, McCloskey DA, Williams J, Dole W and Ellman M. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multi-center, placebo-controlled, double-blind study. *Ann Intern Med* 120:199-206, 1994.
 15. Clegg DO, Reading JC, **Mayes MD**, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, Weisman MH, Lee P, Moreland LW, Neuner R, Gall EP, Clements P, Spindler J, and Lally EV. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheum* 21:105-110, 1994.
 16. Freedman RR, Woodward S, and **Mayes MD**. Nonneural mediation of digital vasodilation during menopausal hot flashes. *Gynecol Obstet Invest* 38:206-209, 1994.
 17. Schottenfeld D, Burns CJ, Gillespie BW, Laing TJ, **Mayes MD**, Heeringa SG, and Alcsér KH. The design of a population based case-control study of systemic sclerosis (scleroderma): commentary on the University of Michigan study. *J Clin Epidemiol* 48:583-586, 1995.
 18. Kirk TZ, Mark ME, Chua CC, Chua BH, and **Mayes MD**. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and TIMP-1 (Tissue Inhibitor of Metalloproteinase) with two forms of TIMP-1. *J Biol Chem* 270:3423-3428, 1995.
 19. Clements PJ, Collier DH, Dixon M, Furst DE, Ingenito F, Lachenbruch PA, Lally EV, Martin RW, Massa M, **Mayes MD**,

- McCloskey DA, Medsger, Jr TA, Moreland LW, Seibold JR, Steen V, Varga J, Weiner S, Weinstein A, Weisman M, White B, and Wigley FM. Inter and intra-observer variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis (SSc). *J Rheumatol* 22:1281-1285, 1995.
20. Moreland LW, Pratt PW, **Mayes MD**, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, and Koopman WJ. Double-blind, placebo-controlled multi-center trial using chimeric monoclonal anti-CD4 antibody cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. *Arthritis Rheum* 38:1581-1588, 1995.
 21. Freedman RR, Baer RP, **Mayes MD**. Blockade of vasospastic attacks by alpha-2, but not alpha-1 adrenergic antagonists in idiopathic Raynaud's disease. *Circulation* 92:1448-1451, 1995.
 22. Freedman RR, **Mayes MD**. Familial aggregation of primary Raynaud's disease. *Arthritis Rheum* 39:1189-1191, 1996.
 23. Burns CJ, Laing TJ, Gillespie BW, Heeringa SG, Alcsér KH, **Mayes MD**, Wasko MCM, Cooper BC, Garabrant DH, Schottenfeld D. The epidemiology of scleroderma among women: Assessment of risk from exposure to silicone and silica. *J Rheum* 23:1904-1911, 1996.
 24. Keenan PA, Jacobson MW, Soleymani RM, **Mayes MD**, Stress ME, Yaladoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. *Neurology* 47:1396-1402, 1996.
 25. Laing TJ, Gillespie BW, Toth MB, **Mayes MD**, Gallavan Jr. RH, Burns CJ, Johanns JR, Cooper BC, Keroack BJ, Wasko MCM, Lacey Jr. JV, Schottenfeld D. Racial differences in scleroderma among Michigan women. *Arthritis Rheum* 40:734-742, 1997.
 26. **Mayes MD**, Buyon JP, Pachman LM, Fleckman P, Giannini EH. Connective Tissue Disease Registries. *Arthritis Rheum* 40:1556-1559, 1997.
 27. Seibold J, Clements P, Furst D, **Mayes M**, McCloskey D, Moreland L, White B, Wigley F, Rocco S, Erikson M, Hannigan J, Martin E, Amento E. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. *J Rheum* 25:302-307, 1998.
 28. Doss B, Jacques SM, Atty S, **Mayes MD**, Qureshi F. Maternal scleroderma: placental findings and perinatal outcome. *Hum Pathol* 29:1524-1530, 1998.
 29. Wigley FM, Korn JH, Csuka ME, Medsger Jr. TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, **Mayes MD**, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double blind study. *Arthritis Rheum* 41:670-677, 1998.
 30. Kirk TZ, **Mayes MD**. IL-1 rescues scleroderma myofibroblast

- from serum-starvation-induced cell death. *Biochem Biophys Res Commun (BBRC)* 255:129-132, 1999.
31. Clements PJ, Furst D, Wong W-K, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. High-dose vs low-dose D-penicillamine in early diffuse systemic sclerosis. Analysis of a two-year, double-blind, randomized, controlled clinical trial. *Arthritis Rheum* 42:1194-1203, 1999.
 32. Lacey Jr JV, Garabrant DH, Laing TJ, Gillespie BW, **Mayes MD**, Cooper BC, Schottenfeld D. Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). *Am J Epidemiol* 149:761-770, 1999.
 33. Clements PJ, Wong W-K, Hurwitz EL, Furst DE, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. *Arthritis Rheum* 42:2372-2380, 1999.
 34. Freedman RR, Girgis RE, **Mayes MD**. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. *J Rheumatol* 26:2386-2388, 1999.
 35. Freedman RR, Girgis RE, **Mayes MD**. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. *Lancet* 354:739, 1999, Research Letter.
 36. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, **Mayes MD**, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Recombinant Human Relaxin in the treatment of scleroderma: A randomized double-blind, placebo-controlled trial. *Ann Intern Med* 132:871-879, 2000.
 37. Clements PJ, Hurwitz EL, Wong W-K, Seibold J, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, and Furst DE. Skin thickness score as a predictor and correlate of outcome in sclerosis: high-dose vs low-dose Penicillamine trial. *Arthritis Rheum* 43:2445-2454, 2000.
 38. Freedman RR, Girgis RE, **Mayes MD**. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. *J Rheumatol* 28:119-121, 2001.
 39. Furst DE, Clements PJ, Wong WK, **Mayes MD**, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger Jr. TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic

- 40:615- sclerosis patients entering a clinical trial. *Rheumatology (Oxford)* 622, 2001.
40. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, **Mayes MD**. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three US cohorts. *Arthritis Rheum* 44:1359-1362, 2001.
 41. Furspan PB, **Mayes MD**, Freedman RR. Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon. *J Rheumatol*, 28:2263-2268, 2001.
 42. Clements PJ, Wong WK, Hurwitz EL, Furst DE, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Seibold JR. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. *Arthritis Rheum* 44:653-661, 2001.
 43. Laing TJ, Schottenfeld D, Lacey JR Jr, Gillespie BW, Garabrant DH, Cooper BC, Heeringa SG, Alcsér KH, **Mayes MD**. Potential risk factors for undifferentiated connective tissue disease among women: implanted medical devices. *Am J Epidemiology* 154:610-617, 2001.
 44. Girgis RE, Gugnani MK, Abrams J, **Mayes MD**. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. *Am J Respir Crit Care Med* 165:1587-1591, 2002.
 45. Doss BJ, Qureshi F, **Mayes MD**, Jacques SM. Vascular and connective tissue histopathologic alterations of the female lower genital tract in scleroderma. *J Rheumatol* 29:1384-1387, 2002.
 46. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, **Mayes MD**, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. *Blood* 100:1602-1610, 2002.
 47. Merkel PA, Herlyn K, Martin RW, Anderson JJ, **Mayes MD**, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM: Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. *Arthritis Rheum* 46:2410-2420, 2002.
 48. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, **Mayes M**, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-Penicillamine in early diffuse systemic sclerosis trial. *Arthritis Rheum* 46:2983-2989, 2002.

49. Garabrant DH, Lacey JV Jr, Laing TJ, Gillespie BW, **Mayes MD**, Cooper BC, Schottenfeld D. Scleroderma and solvent exposure among women. *Am J Epidemiol* 157:493-500, 2003.
50. **Mayes MD**, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large U.S. population. *Arthritis Rheum* 48:2246-2255, 2003.
51. Nash RA, Dansey R, Storek J, Sullivan KM, Georges GE, Bowen JD, Holmberg LA, Kraft GH, **Mayes MD**, McDonagh KT, Chen CS, Dipersio J, LeMaistre CF, Pavletic S, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. *Biol Blood Marrow Transplant* 9:583-591, 2003.
52. **Mayes MD**, O'Donnell D, Rothfield NF, Csuka ME. Minocycline is not effective in systemic sclerosis (SSc): Results of an open-label multicenter trial. *Arthritis Rheum* 50:553-557; 2004.
53. Clements PJ, Seibold JR, Furst DE, **Mayes, M**, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga, J, Weiner SR, Andrews B, Abeles M, Wong WK. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: Lessons Learned. *Semin Arthritis Rheum* 33:249-263, 2004.
54. Chatterjee S, Mark ME, Wooley PH, Lawrence WD, **Mayes MD**. Increased dermal elastic fibers in the tight skin mouse. *Clin Exp Rheumatol* 22:617-620, 2004.
55. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, **Mayes MD**, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. *J Rheumatol (Case Report)* 31:2513-6, 2004.
56. Korn JH, **Mayes M**, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin S, Chatterjee S, Peters H, Coppock J, Herrick A, Merkel P, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Bodin F, Black C, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. *Arthritis Rheum* 50:3985-93, 2004.
57. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz M, Chung J, Fitzgerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, **Mayes MD**, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Correlation of the degree of dyspnea score with health-related quality of life, functional abilities and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis:

58. Furspan PB, Chatterjee S, **Mayes MD**, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. *Rheumatology (Oxford)* 44:488-94, 2005.
59. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, **Mayes MD**, Collier D, Medsger Jr TA, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index (HAQ-DI) in a Systemic Sclerosis Clinical Trial. *J Rheumatol* 32:832-40, 2005.
60. Wigley FM, Lima JA, **Mayes M**, McLain D, Chapin JL, Ward-Able C. The Prevalence of Undiagnosed Pulmonary Arterial Hypertension in Subjects with Connective Tissue Disease at the Secondary Healthcare Level of Community-Based Rheumatologists (UNCOVER Study). *Arthritis Rheum* 52:2125-32, 2005.
61. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, **Mayes MD**, Jin L, Arnett FC Jr. Classification analysis of the transcriptome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. *Arthritis Rheum* 52:865-76, 2005.
62. Chatterjee S, Dombi GW, Severson RK, **Mayes MD**. Risk of Malignancy in Scleroderma: a population-based cohort study. *Arthritis Rheum* 52; 2415-24, 2005.
63. Assassi S, **Mayes MD**, McNearney T, Fischbach M, Reveille JD, Arnett FC, Tan FK. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. *Am J Med* 18:907-11, 2005.
64. Tan FK, Zhou X, Marcum C, Gourh P, Guo X, **Mayes MD**, Jin L, Arnett FC, Jr. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. *Rheumatology (Oxford)* 45:694-702, 2006.
65. Gardner H, Trojanowska M, Smith E, Pannu J, Shearstone J, Bandaru R, Tan FK, Crowel T, Lynes M, Jablonska S, Blaszczyk M, **Mayes MD**. Gene Profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. *Arthritis Rheum* 54:1961-73, 2006.
66. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, **Mayes MD**, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger Jr TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EE, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Minimally important differences in diffuse systemic sclerosis: results from the D-Penicillamine study. *Ann Rheum Dis* 65(10):1325-9, 2006.

67. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. *N Engl J Med* 354:2655-66, 2006 (June).
68. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, **Mayes MD**, Bucala R. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. *Arthritis Rheum* Nov;54(11):3661-9, 2006.
69. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, **Mayes MD**. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. *Arthritis Rheum* 52 (2):318-26, 2007.
70. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, Arnett FC, **Mayes, MD**. Association of the *PTPN22* R620W Polymorphism with anti-topoisomerase-I and anticentromere antibody-positive systemic sclerosis. *Arthritis Rheum* Dec;54(12):3945-53, 2006.
71. Alkassab F, Gourh P, Tan FK, McNearney T, Fischbach M, Ahn C, Arnett FC, **Mayes MD**. An allograft inflammatory factor 1 (*AIFI*) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. *Rheum Oxford*, 46(8):1248-51, 2007.
72. Denton CP, Merkel P, Furst D, Khanna D, Emery P, Hsu V, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen, F, Herrick A, **Mayes M**, Veale D, Haas J, Ledgetter S, Korn J, Black CM, Seibold JR. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-TGF β 1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I/II trial of CAT-192. *Arthritis Rheum* Jan;56(1):323-33, 2007.
73. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Impact of Oral Cyclophosphamide on Health-Related Quality of Life in Patients with active Scleroderma Lung Disease: Results from the Scleroderma Lung Study. *Arthritis Rheum* 56(5):1676-84, 2007.
74. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin D, Gooley TA, Holmberg L, Henstorf G, LeMaistre F, **Mayes MD**, McDonagh KT, McLaughlin B, Moliter JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE. High-Dose Immunosuppressive Therapy (HDIT) and autologous hematopoietic

- cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study. *Blood* 110(8):1388-96, 2007.
75. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel P, Kahaleh B, Wollheim F, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman M, Moreland LW, Rothfield NF, Hsu V, **Mayes M**, McKown KM, Krieg T, Seibold JR. Outcome measurements in scleroderma: results from a Delphi exercise. *J Rheum* 34(3):501-9, 2007.
 76. Suarez-Almazor ME, Kallen MA, Roundtree AK, **Mayes M**. Disease and symptom burden in systemic sclerosis: a patient perspective. *J Rheumatol* Aug; 34:1718-26, 2007.
 77. Assassi S, Arnett FC, Reveille JD, Gourh P, **Mayes MD**. Clinical, immunological, and genetic features of familial systemic sclerosis. *Arthritis Rheum* 56(6):2031-7, 2007.
 78. Alkassab F, **Mayes MD**. Images in Rheumatology: Overlap of Systemic Sclerosis and Rheumatoid Arthritis. *J Rheum* 2007(8); 34:1593-4.
 79. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagle D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connolly K, Metersky M, Furst DE. Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. *Ann Rheum Dis* May 7, 2007. *Epub ahead of print*.
 80. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rithfield N, Metersky M. Effect of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *Am J Resp Crit Care Med* 176:1026-34, 2007.
 81. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton T, **Mayes M**, Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Increased pigmentation diminishes anti-fibrotic response of human skin to ultraviolet A1 phototherapy. *In Press 2007 Arch Dermatology*.
 82. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, **Mayes MD**, Steen VD, Varga J, Furst DE, for the other coauthors of the Scleroderma Clinical Trial Consortium. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Ann Rheum Dis* Sep 24 [Epub ahead of print], 2007.
 83. Khanna D, Hays RD, Park GS, Braun-Moscovici Y, **Mayes MD**, McNearney TA, Hsu V, Clements PJ, Furst DE. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. *Arthritis Rheum* Oct 15;57(7):1280-1286, 2007.

- Clin
84. McNearney TA, Sluka KA, Lisi T, Reveille JD, Fischbach M, **Mayes, MD.** Association of clinical and laboratory parameters to plasma endogenous enkephalin levels in early scleroderma (*Submitted to J Rheum, 2008*).
 85. McNearney TA, Hunnicutt SB, Fischbach M, Friedman AW, Aguilar M, Ahn C, Reveille JD, Lisse Jr, Baethge BA, Goel N, Mayes MD, for the GENISOS Study Group. Self Reported Physical and Mental Function in Systemic Sclerosis: Baseline Evaluation of the Multi-Ethnic GENISOS Cohort. (*Submitted to J Clin Rheum 2008*).

C. INVITED ARTICLES AND REVIEWS:

1. **Mayes MD.** Scleroderma Epidemiology. Rheumatic Disease Clinics of North America 22:751-764, 1996.
2. **Mayes MD.** Epidemiology of systemic sclerosis and related diseases. Curr Opin Rheumatol. 1997;9:557-561.
3. **Mayes MD.** Classification and epidemiology of scleroderma. Semin Cutan Med Surg. 1998;17:22-26.
4. **Mayes MD.** Epidemiologic studies of environmental agents and systemic autoimmune disease. Environ Health Perspect. 107:743-748,1999.
5. **Mayes MD.** Photopheresis and autoimmune diseases. Rheum Dis Clin North Am 26:75-82, 2000.
6. **Mayes MD.** Scleroderma. Pediatr Dermatol. 17:75-83, 2000.
7. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, **Mayes MD**, Varga J, Medsger Jr. T, and Love LA. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243-249, 2000.
8. **Mayes MD.** The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep 2:512-516, 2000.
9. **Mayes, MD.** Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48(5):1190-9, 2003.
10. **Mayes MD.** Scleroderma epidemiology. Rheum Dis Clin North Am 29:239-54, 2003.
11. Steen VD, **Mayes MD**, Merkel PA. Assessment of kidney involvement. Supplement 29: The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 21: S29-31, 2003.
12. Assassi S, **Mayes MD.** The genetics of scleroderma: What every rheumatologist should know. Scleroderma Care Res 1:3-11, 2004.
13. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, Gratwohl A, vanLaar JM, **Mayes MD**, Martin R, McSweeney PA, Muraro PA, Openshaw H, Saccardi R, Sandmaier BM, Forman SJ, Nash RA on behalf of the workshop participants. Feasibility of allogeneic stem cell transplantation for autoimmune disease: Position statement from a

- NIAID and NCI-sponsored international workshop. *Biol Blood Marrow Transplant* 11:862-70, 2005.
14. **Mayes MD.** Race, Scleroderma, and Survival: Why is there a difference? *J Rheumatol* (Editorial) 32:1873-4, 2005.
 15. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch C, Kremers HM, Kwoh CK, Liang MH, **Mayes MD**, Pillemer SR, Reveille JD for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. *Arthritis Rheum* 58:15-25,2008 Jan.
 16. Alkassab F, **Mayes MD.** The Genetics and Genomics of SSc. An Update and Review. 2007 *Curr Rheum Rev* 3:287-96,2007.
 17. Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. *Arthritis Res Ther.* 9 suppl 2:S5, 2007.
 18. Alkassab F, Gourh P, Tan F, Arnett F, **Mayes M.** Comment on: An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis: reply. *Rheumatology* (Oxford). 2008 Mar 7 [Epub ahead of print]
 19. Gourh P, **Mayes MD**, Arnett FC. CTGF polymorphism associated with systemic sclerosis. *N Engl J Med.* 2008 Jan 17;358(3):308-9.

D. CHAPTERS

1. Krakauer RS, **Mayes MD**, and Clough JD. Assays of suppression of lymphocyte function in SLE patients and first order relatives in Mechanisms of Lymphocyte Activation. Proceedings of the 14th International Leucocyte Conference held in Heidelberg, F.R.G., June 7-11, 1981. Klaus Resch Holger Kirchner, Editors. Elsevier/North Holland Biomedical Press.
2. **Mayes MD**, Cathcart M, Dustoor M, et al. The role of immunopathogenesis of progressive systemic sclerosis. Proceedings of the Second International Conference on Progressive Systemic Sclerosis, Austin, TX, October 20, 1982.
3. **Mayes MD**, Reveille JD. Epidemiology, Demographics, and Genetics. *In* Clements P and Furst D (ed): *Systemic Sclerosis*, 2nd edition. Philadelphia, Lippincott Williams & Wilkins, 2004.
4. MacNeil MC, **Mayes MD.** Systemic Sclerosis: Assessing disease activity and outcome in scleroderma. *In* Hochberg, Silman, Weinblatt and Weisman (ed): *Rheumatology* 4e. Elsevier Limited, 2007.
5. **Mayes, MD.** Systemic Sclerosis: Clinical Aspects. *In* Klippel JH, Stone JH, Crofford LJ and White PH (ed): *Primer on the Rheumatic Diseases*, 13th Edition, Atlanta, Springer, 2008.

E. BOOKS

1. Mayes MD. The Scleroderma Book. New York: Oxford University Press, 2nd edition 2005.

F. OTHER PROFESSIONAL COMMUNICATIONS

PRESENTATIONS International and National meetings:

- a. Invited speaker, The Science and Politics of Women's Health in America, WSU, Detroit, May 1993,
- b. Invited speaker, "Environmentally Associated Connective Tissue Disease" (EACTD) session, American College of Rheumatology national meeting, Orlando, FL, October 21, 1996.
- c. Moderator, "Raynaud's Phenomenon and Scleroderma" session, American College of Rheumatology (ACR) national meeting, Washington, DC, November 8-12, 1997.
- d. Invited speaker, NIH/NIAMS workshop on Atypical Rheumatic Diseases and Silicone Breast Implants, April 17, 1997, Bethesda, MD.
- e. Invited speaker, NIH/NIAMS conference on "Emerging Opportunities in Scleroderma Research," Bethesda, MD, December 8-9, 1997.
- f. Invited speaker, NIH/NIEMS/NIAMS workshop on Environmental Agents and Autoimmune Diseases, Research Triangle Park, NC, September 1-3, 1998.
- g. Invited panel member, NIH/NIAMS workshop on Stem Cell Transplants in Auto-Immune Diseases, Bethesda, MD, September 11, 1998.
- h. Invited speaker, First International Conference on the Mammalian Centromere, Taichung, Taiwan, October 4, 1998.
- i. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, San Diego, CA, November 7-12, 1998.
- j. Invited speaker, Society for Pediatric Dermatology, 1999 Annual Meeting, Thompsonville, MI, July 20-23, 1999.
- k. Johns Hopkins University Department of Rheumatology Grand Rounds, "Environmental Triggers in Scleroderma," Baltimore, MD, September 17, 1999.
- l. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, Boston, MA, November 13-17, 1999.
- m. Invited speaker, International Scleroderma Biannual Workshop, Keble College, Oxford, UK July 29 – August 2, 2000.
- n. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, Philadelphia, PA, October 29-November 3, 2000.
- o. Scleroderma: A Treatable Disease. Einstein School of Medicine/Montefiore Medical Center Rheumatology Grand Rounds, Bronx, NY, October 26, 2001.

- p. Scleroderma: A Treatable Disease. Columbia University/Presbyterian Hospital, Rheumatology Grand Rounds, New York, NY, October 26, 2001.
- q. Invited panel member, Workshop on Establishing Core Set of Variables in Scleroderma Care and Research, Portonova, Italy February 2-9, 2002.
- r. Invited speaker, International Scleroderma Biannual Workshop, Woods Hole, MA, USA May 18 - 22, 2002.
- s. Annual Scleroderma Foundation Patient Conference Keynote Speaker, "Update on Scleroderma Research and Treatment," Las Vegas, NV, June 30, 2002.
- t. Invited panel member, Pew Expert Panel on a Health Tracking Network for Autoimmune Disease, sponsored by the Agency for Toxic Substances and Disease Registry (ATSDR), CDC, Atlanta Georgia, Sept. 20, 2002
- u. Invited panel member, NIH/NIAMS Workshop on Collaborative Approaches to Genetics Research in Rheumatic and Autoimmune Skin Diseases, Rockville, MD, June 22, 2003.
- v. Moderator, VIII International Workshop on Scleroderma Research, Trinity College, Cambridge, UK, July 31- August 4, 2004
- w. Invited speaker, Post American College of Rheumatology Symposium "Inside Scleroderma: A Focus on Cardiopulmonary Complications of Systemic Sclerosis," San Antonio, Texas, October 21, 2004
- x. Invited speaker, Annual Scleroderma Foundation Patient Conference "Update on Scleroderma Research and Treatment," Boston, MA, June 18-19, 2005.
- y. Invited speaker, NIAID/NCI Workshop on Feasibility of Allogeneic Hematopoietic stem cell transplantation for autoimmune disease, Topic: Epidemiology of Scleroderma, Bethesda, MD, March 12-13, 2005.
- z. Invited speaker, UCLA sponsored City of Hope conference on Epidemiology of SSc, Los Angeles, CA 10/6/2005.
- aa. Invited speaker, Consensus Conference on Systemic Autoimmune Rheumatic Diseases, Topic: The Clinical Trial as a Probe into Disease Mechanisms of Scleroderma, Toronto, Ontario, Canada, December 3-4, 2005.
- bb. Invited speaker, International Scientific Advisory Board Meeting (Actelion Pharmaceuticals), Athens, Greece, "Update on the Genetics of Scleroderma," April 22, 2006.
- cc. Invited speaker, 9th International Workshop for Scleroderma Research, August 5-9, 2006, Boston, MA.
- dd. Invited speaker, International Workshop on Systemic Sclerosis: Gene Polymorphisms, Clinical Variants and Response to Therapy, Milan Italy, "Genetic Polymorphisms in SSc and SLE – Lessons to be Learned." March 3-10, 2007.
- ee. Invited speaker, Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, Tokyo Japan, "The Epidemiology of Scleroderma," May 18-20, 2007.

- ff. Invited Speaker, American College of Rheumatology Board Review Course, Philadelphia, PA “Scleroderma” March 17, 2007.
- gg. Invited Speaker, Scleroderma Foundation National Patient Conference, Philadelphia, PA “Scleroderma 101,” July 21, 2007.
- hh. Invited speaker, Stanford University Rheumatology Grand Rounds, Palo Alto, CA “The Genetics of Scleroderma: August 9, 2007.
- ii. Invited moderator, American College of Rheumatology national meeting, Boston, MA, Nov 7-11,2007.
- jj. Invited Speaker, American College of Rheumatology Board Review Course, Atlanta, GA “Scleroderma” March 8, 2008.

Presentations at Local and Regional meetings:

1. Invited speaker, Professors in Action, Michigan Chapter of the American College of Physicians annual meeting. Traverse City, MI, September 1995.
2. Invited speaker, ACR Central Regional meeting, “Therapeutic Update in Scleroderma,” Chicago, IL, April 2,1995.
3. Rheumatology Session, Michigan Chapter American College of Physicians meeting, Grand Traverse, MI, September 1988, September 1989, and September 1990 meetings.
4. “Common Problems in Rheumatology for the Practicing Physicians,” Conference sponsored by Wayne State University, Southfield, MI, September 13, 1989.
5. “Update: Medical Management and Treatment of Arthritides” Conference sponsored by Wayne State University, Southfield, MI, September 13, 1989.
6. “Rheumatology Update, Pathogenesis and Treatment of the Rheumatic Diseases,” National Conference sponsored by Wayne State University, Dearborn, MI, October 11-12, 1989.
7. Invited speaker, Professors in Action, Michigan Chapter of the American College of Physicians annual meeting, Traverse City, MI, September, 1996.
8. Department of Medicine, CPC, Discussant, Harper Hospital, Detroit, MI, November 27, 1996.
9. Department of Medicine, CPC, Discussant, Harper Hospital, Detroit, MI, November 26, 1997.
10. “Scleroderma Update,” Michigan Dermatology Society annual meeting, Dearborn, MI, April 22, 1998.
11. Invited speaker, The Cleveland Clinic, Internal Medicine and Rheumatology Grand Rounds “Scleroderma Update,” Cleveland, OH, June 18, 1998.
12. Invited speaker, The Cleveland Rheumatism Society, “Theories on the Pathogenesis of Scleroderma,” Cleveland, OH, June 17, 1998.
13. University of Michigan Rheumatology Grand Rounds, "Scleroderma: the Search for an Environmental Trigger," Ann Arbor, MI, March

- 5, 1999.
14. WSU Division of Rheumatology sponsored symposium for Graduate Medical Education, "New Biologics in Rheumatoid Arthritis," Detroit, MI, May 5, 1999.
 15. University of Western Ontario Rheumatology Grand Rounds, "Therapeutic Options in Scleroderma," "Options in Scleroderma," London, Ontario, May 13, 1999.
 16. Henry Ford Hospital Department of Internal Medicine Grand Rounds, "Diagnosis and Treatment of Systemic Vasculitis," Detroit, MI, June 3, 1999.
 17. Michigan State Medical Society Meeting, Dermatology Update, "Scleroderma: Therapeutic Advances / Elusive Cure," Dearborn, MI, October 31, 2001.
 18. CPC Discussant, Department of Internal Medicine, UT-H, June 17, 2002.
 19. University of Michigan, Rheumatology Grand Rounds, "Scleroderma Clinical Trials and Tribulations," Ann Arbor, MI, October 11, 2002
 20. Symposium on Pulmonary Arterial Hypertension sponsored by the University of Michigan Pulmonary Medicine and CME sections, "Secondary causes of PAH – the Autoimmune Diseases," Livonia, MI, October 12, 2002.
 21. University of Texas – San Antonio, Internal Medicine Grand Rounds "Update on Scleroderma Treatment and Research, January 29, 2003.
 22. San Antonio Area Rheumatism Society "Update on Scleroderma Therapy" January 28, 2003.
 23. International Rheumatology Network sponsored "Update on Scleroderma Therapy," Minneapolis, MN May 17, 2003
 24. Rheumatology on the Beach "New Modalities for Therapy in Scleroderma" Florida, September 21, 2003.
 25. Scleroderma Foundation sponsored expert panel on the status of research and therapy in scleroderma, New York, NY, February 9, 2004.
 26. Texas Medical Center Rheumatology Grand Rounds "Update on Treatment Trials in Scleroderma" UT-H Medical School, March 9, 2004.
 27. CME meeting sponsored by UT-Houston "Approach to the SSc Patient with Dyspnea, April 29, 2004, Houston, Tx.
 28. The International Pulmonary Hypertension Experts Conference "Uncovering PAH Secondary to SSc," New York, NY, June 11, 2004.
 29. MD Anderson Cancer Center GVHD Conference "Current Issues in the Management of Systemic Sclerosis, Houston, TX, June 15, 2004.
 30. Speaker, 4th Annual Cytokine Immunology for the 21st Century, Austin, Tx, August 21, 2004.
 31. Internal Medicine for the Cancer Patient, MD Anderson sponsored conference "Autoimmune Disease and Cancer: Cause, Effect or Coincidence?" Houston, TX, September 10, 2004.
 32. Rheumatology Grand Rounds, University of Washington, Seattle, November 19, 2004.

33. San Antonio Rheumatism Society meeting on 'Updates in Scleroderma', San Antonio TX 9/14/2005.
34. UT San Antonio Health Science Center presentation to Rheumatology Division 'Pathogenesis of Scleroderma' 9/15/2005.
35. Internal Medicine Grand Rounds, Houston Northwest Medical Center, "Overview of Advances in Rheumatology," December 13, 2005.
36. Alabama Rheumatism Society meeting 'Update in Scleroderma' Birmingham, AL 1/11/2006.
37. UAB Rheumatology Grand Rounds 'The Genetics of Scleroderma' Birmingham, AL, 1/12/2006.
38. Invited Speaker, UT Southwestern Rheumatology Division, "Update on Treatment of SSc" August 25, 2006, Dallas.
39. New Orleans Rheumatism Society 'Update on SSc Treatment' New Orleans, LA 8/30/2006.
40. Invited Speaker, Ochsner Clinic, New Orleans, LA, "Update on Treatment of SSc," August 31, 2006.
41. Invited Speaker, University of Arkansas Medical Center, Department of Medicine Grand Rounds, Little Rock, AR, "Treatment of Scleroderma in 2007," January 24, 2007.
42. Invited Speaker, Baylor College of Medicine, "Management & Treatment of SSc in 2007 - Lessons from Clinical Trials, March 29, 2007.
43. Invited Speaker, West Texas Rheumatism Society, Lubbock, TX "The treatment of SSc in 2007," April 27, 2007.
44. Invited Speaker, Park Plaza Hospital, Houston, TX "The Treatment of SSc in 2007," June 13, 2007.
45. Invited Speaker, Louisiana State University, Shreveport, LA " Update on the Treatment of SSc in 2007," July 27, 2007.
46. Invited Speaker, University of Alabama Birmingham, annual Lowe Conference "Genetics and Genomics of SSc" October 5-6, 2007.